Clinical Trials on Obstructive Hydrocephalus in Argentina

Total 239 results

CereVasc Inc
AlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...

Recruiting

The ETCHES I Study (Endovascular Treatment of Communicating Hydrocephalus With an Endovascular Shunt) (ETCHES I)

Hydrocephalus | Hydrocephalus, Communicating

Argentina
CereVasc Inc
AlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...

Recruiting

Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Hydrocephalus | Hydrocephalus, Normal Pressure

Argentina
The Hospital for Sick Children
The International Study Group for Neuroendoscopy (ISGNE); The International...

Completed

A Study Comparing Two Treatments for Infants With Hydrocephalus

Hydrocephalus

Canada, United Kingdom, Spain, India, United States, Poland, Hungary, Turkey, Brazil, Argentina, Germany, Israel, Italy, Netherlands, Russian Federation, Serbia
Hospital Italiano de Buenos Aires

Unknown

Hospitalary Chronic Obstructive Pulmonary Disease Registry

Death | COPD Exacerbations

Argentina
Hospital Italiano de Buenos Aires
Asociacion Argentina Medicina Respiratoria (AAMR)

Unknown

Association Between Testosterone Levels and COPD Severity (COPDTESTO)

Chronic Obstructive Pulmonary Disease | Hypogonadism

Argentina
AstraZeneca

Completed

SABINA INTERNATIONAL

Asthma

Argentina
GlaxoSmithKline

Completed

Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Chile, South Africa, New Zealand
Novartis Pharmaceuticals

Completed

Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (Advantage)

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
Hospital Italiano de Buenos Aires

Unknown

Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery (ILEUS)

Postoperative Ileus

Argentina
Hospital General de Niños Pedro de Elizalde

Completed

Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis (Hypertonic)

Bronchiolitis

Argentina
Novartis Pharmaceuticals

Completed

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
Universidad Nacional de Rosario

Completed

Asthmatic Subjects Could Live Without Short Acting beta2 Agonists (NOSABA)

Asthma Chronic

Argentina
PH&T S.p.A.

Unknown

Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays (PHT-01-12)

Nasal Obstruction | Sneezing | Itching

Argentina
AstraZeneca

Completed

Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America (PUMA PROJECT)

Chronic Obstructive Pulmonary Disease

Venezuela, Colombia, Argentina, Uruguay
Inmunotek S.L.
LAT Research; Xolomon Tree S.L.

Not yet recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract (MM09-SLIM)

Allergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | Allergy to House Dust Mite

Argentina
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Colombia, India, Belgium, Argentina, Czech Republic
AB Science

Completed

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Asthma

Malaysia, Argentina, Peru, Philippines, Ukraine
AstraZeneca

Completed

Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)

Asthma

Argentina
AstraZeneca

Recruiting

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (ATHLOS)

Chronic Obstructive Pulmonary Disease

Germany, Spain, United States, China, Korea, Republic of, Argentina, United Kingdom, Canada
Novartis Pharmaceuticals

Completed

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD (COMBINE)

Chronic Obstructive Pulmonary Disease

Argentina, Dominican Republic, Panama, Mexico, Brazil, Chile, Ecuador, Honduras
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
GlaxoSmithKline

Completed

A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Russian Federation, Ukraine, Mexico
GlaxoSmithKline

Completed

Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Estonia, Ukraine, Korea, Republic of, Norway, Czechia
Novo Nordisk A/S

Terminated

Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD) (iINHALE 8)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Chronic Obstructive Pulmonary Disease

Slovakia, Argentina, India, Turkey, Romania, Taiwan, Thailand
GlaxoSmithKline

Completed

Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Spain, Chile, Germany, Korea, Republic of, Bulgaria, Brazil, Slovakia
Pfizer

Completed

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease

Australia, Netherlands, Canada, Korea, Republic of, Argentina, Hungary, South Africa, France, Russian Federation, Chile, Czechia, Greece, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany
Hoffmann-La Roche

Completed

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Canada, Bulgaria, Hungary, Russian Federation, Denmark, Argentina, Mexico, Poland
AstraZeneca

Completed

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Chronic Obstructive Pulmonary Disease | COPD

United States, Argentina, Canada, Colombia, Mexico, Peru
Pfizer

Completed

A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Costa Rica, Brazil, Chile, Mexico, Argentina
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Novartis Pharmaceuticals

Completed

Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (INSTEAD)

Chronic Obstructive Pulmonary Disease

Colombia, Italy, Switzerland, Argentina, United Kingdom, Mexico, Netherlands, Malaysia, Spain
Pfizer

Terminated

Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Pulmonary Disease, Chronic Obstructive

Australia, Canada, Czech Republic, Croatia, Spain, Hungary, Argentina, Singapore, United Kingdom, Chile
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
Daiichi Sankyo, Inc.

Completed

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

Cachexia

United States, Argentina, Chile, Guatemala, Honduras, Romania
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Argentina, Germany, Spain, Turkey, Guatemala, Mexico, Australia, Denmark, South Africa, Philippines
Pfizer

Completed

A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Australia, United Kingdom, Argentina, Germany, India
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Korea, Republic of, Argentina, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Canada, India, Bulgaria, Poland
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
AstraZeneca

Active, not recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Denmark, Italy, United Kingdom, Canada, Germany, Turkey, Argentina, South Africa, Spain, Poland, Bulgaria, Mexico, Netherlands
GlaxoSmithKline

Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Chile, Sweden, Spain, Hungary, Czechia, Norway
Novartis

Completed

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

Chronic Obstructive Pulmonary Disease

Russian Federation, United Kingdom, Spain, Germany, Argentina, Italy, Netherlands, Switzerland, Turkey, France, Czech Republic, Hungary, Slovakia, Peru, Korea, Republic of, Colombia, Israel, Chile, Denmark, Ecuador, Egypt, Estonia, ... and more
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Pulmonary Disease, Chronic Obstructive

United States, Sweden, Australia, Hungary, Bulgaria, South Africa, Poland, Slovakia, India, Canada, Argentina, Czech Republic, Chile, New Zealand, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Argentina, Australia, Canada, Mexico, New Zealand, South Africa
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
Novartis

Completed

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) (GLOW2)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Romania, Ukraine, United States, Chile, Greece, Peru

Clinical Trials on Obstructive Hydrocephalus in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations